Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight The cutaneous T-cell lymphoma clinical trial analysis ...

Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval ...

Phase 2 trial findings show enpatoran reduced skin disease activity in patients with SLE and cutaneous lupus erythematosus.

For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the research ...

Please provide your email address to receive an email when new articles are posted on . Phase 2a interim data show 100% of patients achieving the primary endpoint of skin toxicity improvement. Also, ...

The repair of skin following injury is orchestrated by a complex interplay of inflammatory signals, cell migration and vascular remodelling. Among the key regulators are catecholamines—adrenaline and ...

In a recent study published in Cell, researchers studied the social relevance of G protein-coupled receptor (GPCR) Mrgprb4-lineage touch neurons in sexual touch and receptivity. The sensation of a ...

Niigata, Japan - A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata ...

A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata University Graduate ...